ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global End-Stage Renal Disease (ESRD) Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-23R6928
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global End Stage Renal Disease ESRD Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global End-Stage Renal Disease (ESRD) Drugs Market Research Report 2025

Code: QYRE-Auto-23R6928
Report
September 2025
Pages:73
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
CTI BioPharma Corp
Merck& Co. Inc
Novartis
Prolong Pharmaceuticals LLC
VESSL Therapeutics Ltd

End-Stage Renal Disease (ESRD) Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

End-Stage Renal Disease (ESRD) Drugs Market

End-Stage Renal Disease (ESRD) Drugs Market

The global market for End-Stage Renal Disease (ESRD) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for End-Stage Renal Disease (ESRD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding End-Stage Renal Disease (ESRD) Drugs.
The End-Stage Renal Disease (ESRD) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global End-Stage Renal Disease (ESRD) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the End-Stage Renal Disease (ESRD) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of End-Stage Renal Disease (ESRD) Drugs Market Report

Report Metric Details
Report Name End-Stage Renal Disease (ESRD) Drugs Market
CAGR 5%
Segment by Type
  • Calcium Succinate
  • Mk-3866
  • Pacritinib
  • Sanguinate
  • Tesidolumab
  • Others
Segment by Application
  • Hospital
  • Clinic
  • ICU
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company CTI BioPharma Corp, Merck & Co Inc, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of End-Stage Renal Disease (ESRD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of End-Stage Renal Disease (ESRD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the End-Stage Renal Disease (ESRD) Drugs Market report?

Ans: The main players in the End-Stage Renal Disease (ESRD) Drugs Market are CTI BioPharma Corp, Merck & Co Inc, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd

What are the Application segmentation covered in the End-Stage Renal Disease (ESRD) Drugs Market report?

Ans: The Applications covered in the End-Stage Renal Disease (ESRD) Drugs Market report are Hospital, Clinic, ICU, Others

What are the Type segmentation covered in the End-Stage Renal Disease (ESRD) Drugs Market report?

Ans: The Types covered in the End-Stage Renal Disease (ESRD) Drugs Market report are Calcium Succinate, Mk-3866, Pacritinib, Sanguinate, Tesidolumab, Others

1 End-Stage Renal Disease (ESRD) Drugs Market Overview
1.1 Product Definition
1.2 End-Stage Renal Disease (ESRD) Drugs by Type
1.2.1 Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Calcium Succinate
1.2.3 Mk-3866
1.2.4 Pacritinib
1.2.5 Sanguinate
1.2.6 Tesidolumab
1.2.7 Others
1.3 End-Stage Renal Disease (ESRD) Drugs by Application
1.3.1 Global End-Stage Renal Disease (ESRD) Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ICU
1.3.5 Others
1.4 Global End-Stage Renal Disease (ESRD) Drugs Market Size Estimates and Forecasts
1.4.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue 2020-2031
1.4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales 2020-2031
1.4.3 Global End-Stage Renal Disease (ESRD) Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 End-Stage Renal Disease (ESRD) Drugs Market Competition by Manufacturers
2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global End-Stage Renal Disease (ESRD) Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of End-Stage Renal Disease (ESRD) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Product Type & Application
2.7 Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Date of Enter into This Industry
2.8 Global End-Stage Renal Disease (ESRD) Drugs Market Competitive Situation and Trends
2.8.1 Global End-Stage Renal Disease (ESRD) Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest End-Stage Renal Disease (ESRD) Drugs Players Market Share by Revenue
2.8.3 Global End-Stage Renal Disease (ESRD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global End-Stage Renal Disease (ESRD) Drugs Market Scenario by Region
3.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2020-2031
3.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2020-2025
3.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2026-2031
3.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2020-2031
3.3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2020-2025
3.3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2026-2031
3.4 North America End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.4.1 North America End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2031)
3.4.3 North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.5.1 Europe End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2031)
3.5.3 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.7.1 Latin America End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2031)
3.7.3 Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2020-2031)
4.1.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2020-2025)
4.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2026-2031)
4.1.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2020-2031)
4.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2020-2031)
4.2.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2020-2025)
4.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2026-2031)
4.2.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2020-2031)
4.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2020-2031)
5.1.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2020-2025)
5.1.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2026-2031)
5.1.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2020-2031)
5.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2020-2031)
5.2.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2020-2025)
5.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2026-2031)
5.2.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2020-2031)
5.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 CTI BioPharma Corp
6.1.1 CTI BioPharma Corp Company Information
6.1.2 CTI BioPharma Corp Description and Business Overview
6.1.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.1.5 CTI BioPharma Corp Recent Developments/Updates
6.2 Merck & Co Inc
6.2.1 Merck & Co Inc Company Information
6.2.2 Merck & Co Inc Description and Business Overview
6.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.2.5 Merck & Co Inc Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Company Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Prolong Pharmaceuticals LLC
6.4.1 Prolong Pharmaceuticals LLC Company Information
6.4.2 Prolong Pharmaceuticals LLC Description and Business Overview
6.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.4.5 Prolong Pharmaceuticals LLC Recent Developments/Updates
6.5 VESSL Therapeutics Ltd
6.5.1 VESSL Therapeutics Ltd Company Information
6.5.2 VESSL Therapeutics Ltd Description and Business Overview
6.5.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio
6.5.5 VESSL Therapeutics Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 End-Stage Renal Disease (ESRD) Drugs Industry Chain Analysis
7.2 End-Stage Renal Disease (ESRD) Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 End-Stage Renal Disease (ESRD) Drugs Production Mode & Process Analysis
7.4 End-Stage Renal Disease (ESRD) Drugs Sales and Marketing
7.4.1 End-Stage Renal Disease (ESRD) Drugs Sales Channels
7.4.2 End-Stage Renal Disease (ESRD) Drugs Distributors
7.5 End-Stage Renal Disease (ESRD) Drugs Customer Analysis
8 End-Stage Renal Disease (ESRD) Drugs Market Dynamics
8.1 End-Stage Renal Disease (ESRD) Drugs Industry Trends
8.2 End-Stage Renal Disease (ESRD) Drugs Market Drivers
8.3 End-Stage Renal Disease (ESRD) Drugs Market Challenges
8.4 End-Stage Renal Disease (ESRD) Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
CTI BioPharma Corp
Merck& Co. Inc
Novartis
Prolong Pharmaceuticals LLC
VESSL Therapeutics Ltd
List of Tables
 Table 1. Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global End-Stage Renal Disease (ESRD) Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global End-Stage Renal Disease (ESRD) Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global End-Stage Renal Disease (ESRD) Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market End-Stage Renal Disease (ESRD) Drugs Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of End-Stage Renal Disease (ESRD) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of End-Stage Renal Disease (ESRD) Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global End-Stage Renal Disease (ESRD) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in End-Stage Renal Disease (ESRD) Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Type (2020-2025)
 Table 51. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Type (2026-2031)
 Table 52. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Application (2020-2025)
 Table 61. Global End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Application (2026-2031)
 Table 62. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Application (2026-2031)
 Table 70. CTI BioPharma Corp Company Information
 Table 71. CTI BioPharma Corp Description and Business Overview
 Table 72. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product
 Table 74. CTI BioPharma Corp Recent Developments/Updates
 Table 75. Merck & Co Inc Company Information
 Table 76. Merck & Co Inc Description and Business Overview
 Table 77. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product
 Table 79. Merck & Co Inc Recent Developments/Updates
 Table 80. Novartis AG Company Information
 Table 81. Novartis AG Description and Business Overview
 Table 82. Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Novartis AG End-Stage Renal Disease (ESRD) Drugs Product
 Table 84. Novartis AG Recent Developments/Updates
 Table 85. Prolong Pharmaceuticals LLC Company Information
 Table 86. Prolong Pharmaceuticals LLC Description and Business Overview
 Table 87. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product
 Table 89. Prolong Pharmaceuticals LLC Recent Developments/Updates
 Table 90. VESSL Therapeutics Ltd Company Information
 Table 91. VESSL Therapeutics Ltd Description and Business Overview
 Table 92. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product
 Table 94. VESSL Therapeutics Ltd Recent Developments/Updates
 Table 95. Key Raw Materials Lists
 Table 96. Raw Materials Key Suppliers Lists
 Table 97. End-Stage Renal Disease (ESRD) Drugs Distributors List
 Table 98. End-Stage Renal Disease (ESRD) Drugs Customers List
 Table 99. End-Stage Renal Disease (ESRD) Drugs Market Trends
 Table 100. End-Stage Renal Disease (ESRD) Drugs Market Drivers
 Table 101. End-Stage Renal Disease (ESRD) Drugs Market Challenges
 Table 102. End-Stage Renal Disease (ESRD) Drugs Market Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Product Picture of End-Stage Renal Disease (ESRD) Drugs
 Figure 2. Global End-Stage Renal Disease (ESRD) Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global End-Stage Renal Disease (ESRD) Drugs Market Share by Type: 2024 & 2031
 Figure 4. Calcium Succinate Product Picture
 Figure 5. Mk-3866 Product Picture
 Figure 6. Pacritinib Product Picture
 Figure 7. Sanguinate Product Picture
 Figure 8. Tesidolumab Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global End-Stage Renal Disease (ESRD) Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global End-Stage Renal Disease (ESRD) Drugs Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Clinic
 Figure 14. ICU
 Figure 15. Others
 Figure 16. Global End-Stage Renal Disease (ESRD) Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global End-Stage Renal Disease (ESRD) Drugs Market Size (2020-2031) & (US$ Million)
 Figure 18. Global End-Stage Renal Disease (ESRD) Drugs Sales (2020-2031) & (K Pcs)
 Figure 19. Global End-Stage Renal Disease (ESRD) Drugs Average Price (USD/Pcs) & (2020-2031)
 Figure 20. End-Stage Renal Disease (ESRD) Drugs Report Years Considered
 Figure 21. End-Stage Renal Disease (ESRD) Drugs Sales Share by Manufacturers in 2024
 Figure 22. Global End-Stage Renal Disease (ESRD) Drugs Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest End-Stage Renal Disease (ESRD) Drugs Players: Market Share by Revenue in End-Stage Renal Disease (ESRD) Drugs in 2024
 Figure 24. End-Stage Renal Disease (ESRD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global End-Stage Renal Disease (ESRD) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2020-2031)
 Figure 27. North America End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2020-2031)
 Figure 31. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2020-2031)
 Figure 32. Germany End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2020-2031)
 Figure 39. China End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Latin America End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE End-Stage Renal Disease (ESRD) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of End-Stage Renal Disease (ESRD) Drugs by Type (2020-2031)
 Figure 60. Global Revenue Market Share of End-Stage Renal Disease (ESRD) Drugs by Type (2020-2031)
 Figure 61. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Type (2020-2031)
 Figure 62. Global Sales Market Share of End-Stage Renal Disease (ESRD) Drugs by Application (2020-2031)
 Figure 63. Global Revenue Market Share of End-Stage Renal Disease (ESRD) Drugs by Application (2020-2031)
 Figure 64. Global End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Application (2020-2031)
 Figure 65. End-Stage Renal Disease (ESRD) Drugs Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions